SynthesisChest2021
Lung Histopathology in Coronavirus Disease 2019 as Compared With Severe Acute Respiratory Sydrome and H1N1 Influenza: A Systematic Review.
Synthesis in Chest, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 110 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
110 citing papers in PubMed, 4 syntheses or guidelines pooled it, 183 citations in OpenAlex.
- Histopathological findings and clinicopathologic correlation in COVID-19: a systematic review.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2021Pooled it
- Postmortem Findings Associated With SARS-CoV-2: Systematic Review and Meta-analysis.The American journal of surgical pathology · 2021Pooled it
- Pulmonary Embolism and Deep Vein Thrombosis in COVID-19: A Systematic Review and Meta-Analysis.Radiology · 2021Pooled it
- Systematic Review of Microthrombi in COVID-19 Autopsies.Acta haematologica · 2021Pooled it
- Clinico-histopathologic and single-nuclei RNA-sequencing insights into cardiac injury and microthrombi in critical COVID-19.JCI insight · 2022Trial
- Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.Lancet (London, England) · 2022Trial
- Phase I study in healthy participants to evaluate safety, tolerability, and pharmacokinetics of inhaled nezulcitinib, a potential treatment for COVID-19.Clinical and translational science · 2021Trial
- Blood fibrocytes are associated with severity and prognosis in COVID-19 pneumonia.American journal of physiology. Lung cellular and molecular physiology · 2021Trial
- Performance of the Ventilatory Ratio to Predict Intubation in Patients With COVID-19 Acute Respiratory Distress Syndrome.Critical care explorations · 2026Article
- A longitudinal study of quantitative pulmonary dynamic contrast enhanced MRI following COVID-19 infection.Respiratory research · 2026Article
- Deep learning-assisted, pathogenesis-informed lung histopathology scoring in preclinical mouse models of SARS-CoV-2 and influenza A infection.Frontiers in immunology · 2026Article
- The Effects of Cyproheptadine on Severe COVID-19 From the I-SPY COVID Adaptive Platform Trial.CHEST critical care · 2025Article
- Long-Term Cardiopulmonary Function After COVID-19-Associated Acute Respiratory Distress Syndrome: A Multicenter Case-Control Study.Critical care explorations · 2025Article
- Post-mortem lung biopsies in fatal Covid-19 acute respiratory distress syndrome: a prospective cohort study of 169 patients (HISTOCOVID).Annals of intensive care · 2025Article
- Clinicopathologic Features of Isolated AFOP Nodules Radiologically Mimicking Malignancy in Post COVID-19 Patients: A Case Series Study.Journal of clinical medicine · 2025Article
- Early nintedanib deployment in COVID-19 interstitial lung disease (ENDCOV-I): study protocol of a randomised, double-blind, placebo-controlled trial.BMJ open respiratory research · 2025Article
- Article
- Clinical significance of cytokeratin 19 fragment in COVID-19 patients: a retrospective study.Frontiers in public health · 2025Article
- Contribution of intrapulmonary shunt to the pathogenesis of profound hypoxaemia in viral infection: a mechanistic discussion with an illustrative case.Journal of the Intensive Care Society · 2024Article
- The Impact of Pentraxin 3 Serum Levels and Angiotensin-Converting Enzyme Polymorphism on Pulmonary Infiltrates and Mortality in COVID-19 Patients.Biomedicines · 2024Article
50 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
27 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundPatients with severe coronavirus disease 2019 (COVID-19) have respiratory failure with hypoxemia and acute bilateral pulmonary infiltrates, consistent with ARDS. Respiratory failure in COVID-19 might represent a novel pathologic entity. RESEARCH QUESTION: How does the lung histopathology described in COVID-19 compare with the lung histopathology described in SARS and H1N1 influenza? STUDY DESIGN AND
methodsWe conducted a systematic review to characterize the lung histopathologic features of COVID-19 and compare them against findings of other recent viral pandemics, H1N1 influenza and SARS. We systematically searched MEDLINE and PubMed for studies published up to June 24, 2020, using search terms for COVID-19, H1N1 influenza, and SARS with keywords for pathology, biopsy, and autopsy. Using PRISMA-Individual Participant Data guidelines, our systematic review analysis included 26 articles representing 171 COVID-19 patients; 20 articles representing 287 H1N1 patients; and eight articles representing 64 SARS patients.
resultsIn COVID-19, acute-phase diffuse alveolar damage (DAD) was reported in 88% of patients, which was similar to the proportion of cases with DAD in both H1N1 (90%) and SARS (98%). Pulmonary microthrombi were reported in 57% of COVID-19 and 58% of SARS patients, as compared with 24% of H1N1 influenza patients.
interpretationDAD, the histologic correlate of ARDS, is the predominant histopathologic pattern identified in lung pathology from patients with COVID-19, H1N1 influenza, and SARS. Microthrombi were reported more frequently in both patients with COVID-19 and SARS as compared with H1N1 influenza. Future work is needed to validate this histopathologic finding and, if confirmed, elucidate the mechanistic underpinnings and characterize any associations with clinically important outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.